Intergroupe Francophone De Cancerologie Thoracique

This study tests a new combination of chemotherapy drugs (paclitaxel and carboplatin) plus an immunotherapy drug (durvalumab) as a first treatment for people with extensive-stage small cell lung cancer. The goal is to see if this mix works better than the standard treatment. Abou…

This study tests whether adding an immunotherapy drug (atezolizumab) to a standard chemotherapy (paclitaxel) and a targeted therapy (bevacizumab) can help people with advanced non-squamous lung cancer whose disease has continued to grow after prior chemotherapy and immunotherapy.…

This study tests whether combining two targeted drugs, encorafenib and binimetinib, can shrink tumors in people with a specific genetic mutation (BRAF V600E) in advanced non-small cell lung cancer. About 119 participants will receive the drug combination. The main goal is to see …

This study tests two treatment options for people with advanced ALK-positive non-small cell lung cancer who have not had treatment yet. One group gets the targeted drug brigatinib alone, and the other gets brigatinib plus chemotherapy. The goal is to see if the combination helps …

This study tests a drug called lorlatinib in people with a rare, advanced lung cancer (ROS1-positive non-small cell lung cancer) that stopped responding to initial targeted therapy. About 54 participants will receive lorlatinib to see if it can shrink tumors and delay cancer grow…

This study looks at whether adding the immunotherapy drug atezolizumab to standard chemotherapy helps elderly patients (70+) with advanced non-small cell lung cancer live longer. About 510 participants will receive either chemo alone or chemo plus atezolizumab. The goal is to see…